Alumis Inc. Common Stock

NASDAQ:ALMS

Biotechnology

Healthcare
$4.84 +0.91%

+$0.21 today

Market cap
$626.47M
Beta
-0.54
P/E (TTM)
-12.2
EPS (TTM)
-$1.90
52W Low $2.76High $30.60

Volume 1.86M

Average 1.31M

Returns on capital

Alumis Inc. Common Stock management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management

ROE

-80.8%

avg -22.7%

ROIC

-120.2%

avg -141.6%

ROA

-59.1%

avg -105.4%

Analysis

ROA is currently the strongest return metric at -59.1% versus its period average of -105.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Martin Babler

President, Chief Executive Officer & ChairmanUSD 1.21M61745.88K0.60%

David Goldstein

Chief Scientific OfficerUSD 821.19K60——

Jorn Drappa

Chief Medical Officer & Head of Research and DevelopmentUSD 817.06K6156.30K0.05%

Roy C. Hardiman

Chief Business & Strategy OfficerUSD 619.84K66207.09K0.17%

John R. Schroer

Chief Financial Officer—6123.92K0.02%

Mark Bradley

Chief Development Officer—60——

Sanam Pangali

Chief Legal Officer & Corporate Secretary—429.41K<0.01%

Kolbot By

Senior Vice President & Head of Technical Operations————

Philip Nunn

Senior Vice President of Pharmacology & Project Team Leader————

Claire Langrish

Senior Vice President & Head of Immunology and Translational Science————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 2, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

32

$56.87M

Sells

15

$1.57M

Net Transaction Value

+$55.30M

Net buying

Most Active

AKKARAJU SRINIVAS

19 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Nov 2, 26

Hardiman Roy C.

Direct

Sell$4.3K
Nov 2, 26

Goldstein David M

Direct

Sell$4.1K
Nov 2, 26

Drappa Jorn

Direct

Sell$3.9K
Nov 2, 26

Bradley Mark Christopher

Direct

Sell$4.1K
Nov 2, 26

Pangali Sanam

Direct

Sell$2.2K
Nov 2, 26

Schroer John R.

Direct

Sell$5.2K
Sep 8, 26

AKKARAJU SRINIVAS

Indirect

Sell$507K
Sep 8, 26

AKKARAJU SRINIVAS

Indirect

Sell$507K
Sep 8, 26

AKKARAJU SRINIVAS

Indirect

Buy$2.9M
Sep 8, 26

AKKARAJU SRINIVAS

Indirect

Buy$2.9M

1–10 of 47

Summary

Insiders reported 32 buys worth $56.87M and 15 sells worth $1.57M over the last 12 months. That adds up to net buying of $55.30M. AKKARAJU SRINIVAS was the most active insider with 19 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A2 analysts
RevenueN/AN/AN/A
+105.6% (5yr)5 analysts
Net IncomeN/AN/AN/A
N/A5 analysts
EBITN/AN/AN/A
N/A —

Analysis

Forward estimates point to Revenue at +105.6% (5yr), giving you a quick read on expected growth from here.

Competitors

Who does Alumis Inc. Common Stock compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about ALMS's management, answered from reported figures.

Who manages ALMS?

Alumis Inc. Common Stock (ALMS) lists 10 active executives. The top listed executive is Jorn Drappa, Chief Medical Officer & Head of Research and Development.

Are ALMS insiders buying or selling?

Recent insider activity shows net buying of $277.43M.